How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 diabetes and established cardiovascular (CV) disease, empagliflozin given in addition to standard of care reduced the risk of CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS: Effects of potential mediators, identified post hoc, on the HR for CV death with empagliflozin versus placebo were analyzed by Cox regression models, with treatment group adjusted for the baseline value of the variable and its change from baseline or updated mean (i.e., considering all prior values), each as a time-dependent covariate. HRs were compared with a model without adjustment for covariates. Multivariable analyses also were performed. RESULTS: Changes in hematocrit and hemoglobin mediated 51.8% and 48.9%, respectively, of the effect of empagliflozin versus placebo on the risk of CV death on the basis of changes from baseline, with similar results in analyses on the basis of updated means. Smaller mediation effects (maximum 29.3%) were observed for uric acid, fasting plasma glucose, and HbA1c. In multivariable models, which incorporated effects of empagliflozin on hematocrit, fasting glucose, uric acid, and urine albumin:creatinine ratio, the combined changes from baseline provided 85.2% mediation, whereas updated mean analyses provided 94.6% mediation of the effect of empagliflozin on CV death. CONCLUSIONS: In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both have been identified as important determinants of the heart failure benefits of these drugs in trials of patients with type 2 diabetes.”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [32]
In the citing paper
“Those that appear particularly plausible include effects on volume status, natriuresis, expansion of red blood cell mass, and myocardial energetics (34,36,59,62,64).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
In the citing paper
“Thus, the mechanisms by which SGLT2 inhibitors reduce the risk for HF are not attributable to improved glycemic control (59).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
Citations
Cites
Baron, R. M., & Kenny, D. A. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.51.6.1173 · Cited by 91,532 · cited 2×
“A traditional mediation analysis as originally proposed by Baron and Kenny (12) was used, taking the time-dynamic evolvement of both the potential mediators and the outcome CV death into account.”
Method(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Introduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationUric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 1×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundSelf-citationLow Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155 · cited 1×
“Therefore, many participants in this trial likely had unrecognized left ventricular dysfunction, particularly diastolic dysfunction, which may eventually lead to clinical heart failure with preserved ejection fraction (25).”
Background
Research works printed but not linked: 2
- Fitchett, Further exploration of the cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease in EMPA-REG OUTCOME, J Am Coll Cardiol
- Boehringer Ingelheim. Empagliflozin (Jardiance®) to be studied in chronic kidney disease. 2017. Available from https://www.boehringer-ingelheim.com/press-release/empagliflozin-be-studied-chronic-kidney-disease. Accessed 6 September 2017
Cited by
Items 701–762 of 762
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13010696
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648931
Wong, C. K. H., Lau, K. T. K., Tang, E. H. M., Lee, C. H., Lee, C. Y. Y., Woo, Y. C., Au, I. C. H., Tan, K. C. B., & Lui, D. T. W. (2022) · Figshare · doi:10.6084/m9.figshare.20003398
Tanaka, A., Toyoda, S., Imai, T., Shiina, K., Tomiyama, H., Matsuzawa, Y., Okumura, T., Kanzaki, Y., Onishi, K., Kiyosue, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16570283
Hasebe, M., Yoshiji, S., Keidai, Y., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., Harada, N., Hamasaki, A., & Inagaki, N. (2024) · Figshare · doi:10.6084/m9.figshare.26575994
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648940
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648946
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648919
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648913
Tanaka, A., Imai, T., Toyoda, S., Sugimoto, K., Yoshida, R., Furuta, M., & Node, K. (2023) · Figshare · doi:10.6084/m9.figshare.23639976
Li, M., Yi, T., Fan, F., Qiu, L., Wang, Z., Weng, H., Ma, W., Zhang, Y., & Huo, Y. (2022) · Figshare · doi:10.6084/m9.figshare.20374627
Li, M., Yi, T., Fan, F., Qiu, L., Wang, Z., Weng, H., Ma, W., Zhang, Y., & Huo, Y. (2022) · Figshare · doi:10.6084/m9.figshare.20374624
Additional file 2 of Effect of high-fat diet and empagliflozin on cardiac proteins in mice
Pan, X., Chen, S., Chen, X., Ren, Q., Yue, L., Niu, S., Li, Z., Zhu, R., Chen, X., Jia, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21341092
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13010687
Lim, J., Choi, Y.-J., Kim, B. S., Rhee, T.-M., Lee, H.-J., Han, K.-D., Park, J.-B., Na, J. O., Kim, Y.-J., Lee, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26606821
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648928
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648925
Giugliano, D., Longo, M., Scappaticcio, L., Bellastella, G., Maiorino, M. I., & Esposito, K. (2021) · Figshare · doi:10.6084/m9.figshare.17254158
Ferrannini, G., Rosenthal, N. R., Hansen, M. K., & Ferrannini, E. (2022) · Figshare · doi:10.6084/m9.figshare.20226992
Self-citationLi, M., Yi, T., Fan, F., Qiu, L., Wang, Z., Weng, H., Ma, W., Zhang, Y., & Huo, Y. (2022) · Figshare · doi:10.6084/m9.figshare.20374615
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648937
Tanaka, A., Shimabukuro, M., Teragawa, H., Okada, Y., Takamura, T., Taguchi, I., Toyoda, S., Tomiyama, H., Ueda, S., Higashi, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14870309
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648910
Li, M., Yi, T., Fan, F., Qiu, L., Wang, Z., Weng, H., Ma, W., Zhang, Y., & Huo, Y. (2022) · Figshare · doi:10.6084/m9.figshare.20374612
Li, M., Yi, T., Fan, F., Qiu, L., Wang, Z., Weng, H., Ma, W., Zhang, Y., & Huo, Y. (2022) · Figshare · doi:10.6084/m9.figshare.20374621
Canet Suquillo, F. G. (2023) · Repository of Digital Objects for Teaching Research and Culture (University of Valencia)
Rynkiewicz, A. K. K. I. K., Sadowski, J. K. K. I. K., Nowek, P. K. K. I. K., & Cygański, P. K. K. I. K. (2018) · Via Medica Journals
Kontrola czynników ryzyka sercowo-naczyniowego u pacjentów po zawale serca
(2019) · Homo Politicus (Academy of Humanities and Economics in Lodz)
Cazorla‐Bak, M. P. (2021) · TSpace (University of Toronto)
Emerging Role Of Multifaceted Drugs In Diabetes Care
Chaudhari, J. B. (2025) · African Journal of Biomedical Research · doi:10.53555/ajbr.v27i6s.8507
КАРДИОПРОТЕКТИВНЫЕ МЕХАНИЗМЫ ИНГИБИТОРОВ НАТРИЙ-ГЛЮКОЗНОГО КОТРАНСПОРТЕРА 2 ТИПА
М., М. А., Н., М. Т., & К., М. Н. (n.d.) · CyberLeninK (CyberLeninka)
Gosmanov, A. R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf690
Rheumatological Perspectives on Sodium-Glucose Cotransporter-2 Inhibitors (Literature review)
Yehudіna, Y. D., & Trypilka, S. (2025) · Family medicine European practices · doi:10.30841/2786-720x.4.2025.349515
Visram, A. (2021) · TSpace (University of Toronto)
Prevention of Heart Failure in People With Diabetes
Pandey, A., & Hernandez, A. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00015-x
Ceriello, A., Fontanella, A., Attardo, T. M., Beltramello, G., Fierro, A., Prattichizzo, F., Pellegrini, V., Fiore, M. S., Menis, E. D., Maffettone, A., et al. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04238-1
Nanayakkara, N., Huang, M. L., Gerche, A. L., Kaye, D. M., Cooper, M. E., Esler, M. D., Reutens, A. T., Shaw, J. E., Jenkins, A., & Cohen, N. D. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00281-9 · Cited by 1
“Reduced plasma volume, as indicated by increased haematocrit, may also be a factor, a mediation analysis of the EMPA-REG OUTCOME trial showed that the strongest statistical association with reduced cardiovascular death was (higher) haematocrit [11].”
Caradu, C. (2020) · theses.fr (ABES) · doi:10.70675/7e30d752z9f28z4e3cz859ezdf2097118a58 · Cited by 1
Huang, Q., Zou, X., Boyko, E. J., Lian, Z., Zhou, X., Han, X., & Ji, L. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag196
Challenges of Modeling Biomarker Effects on Time-to-Event Outcomes
Wang, T., & Qu, Y. (2026) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2026.2669295
Kazuaki, N. (2026) · Cureus · doi:10.7759/cureus.110372
“…have also been shown to reduce the risk of cardiovascular death and heart failure in patients with type 2 diabetes with a history of cardiovascular disease or at high cardiovascular risk, with contributing factors reported to include increases in hemoglobin (Hb) and hematocrit (Ht) levels [4,5].”
Andersen, C. F., Larsen, J. H., Omar, M., Nouhravesh, N., Kistorp, C., Tuxen, C., Knop, F. K., Forman, J. L., Davidovski, F. S., Køber, L., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03216-x
“Uric acid lowering has been proposed to partially mediate the clinical benefits observed with empagliflozin [28], further highlighting the potential importance of this finding.”
Karaköse, S., Doğan, B., Ergül, F., & Güney, İ. (2026) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20251460
“This mechanism is considered a potential cause for the observed increase in Hb and Hct levels 22-24 .”
Raaschou-Pedersen, D. E. T., Andreasen, C. R., Kovalova, T., Branch, K. R., Prato, S. D., Lam, C. S. P., Lópes, R. D., Pratley, R. E., Rosenstock, J., Sattar, N. A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71062
Jurin, I., Hadžibegović, I., Pavlov, M., Marović, M., Čikara, T., & Lucijanić, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145465
“Mechanistically, the SGLT2i-associated hemoglobin rise is widely interpreted as reflecting several convergent processes [5–10 , 30].”
Potupchik, T. V., Veselova, O. F., Evert, L., Pashkova, I., Abbasova, S., Alieva, A., & Abbasova, S. (2026) · Vrach · doi:10.29296/25877305-2026-07-11
Zhang, Y., Xiao, X., Yan, Q., Huang, D., & Wang, W. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1726611
“ICAM1 is involved in inflammatory responses and immune regulation, linking HFpEF and HUA pathophysiology (29, 30).”
Altıntaş, A., Özer, M. T., Tepe, Ö., & Sarıyıldırım, A. (2026) · International Journal of Translational Medicine · doi:10.20944/preprints202608.2095.v1
Metabolic and Lipoprotein Changes in Type 2 Diabetes Patients Treated with Empagliflozin
Habeos, E. E., Markantes, G. Κ., Parthymou, A., Dimitropoulos, K., Habeos, G. I., Papasotiriou, M., Marangos, M. N., & Chartoumpekis, D. V. (2026) · Biomedicines · doi:10.3390/biomedicines14092016
“Read together with the mediation analyses in which hemoglobin accounted for a substantial share of the cardiovascular benefit of these agents [17,46], the direction and timing of our observations position the erythropoietic response as an early and reproducible effect of SGLT2 inhibition rather…”
Урунбаева, Д. А., Нажмутдинова, Д. К., Sadikova, N. G., & Д.С., Г. (2023) · Research Focus International Scientific Journal · doi:10.66073/researchfocus.v2i1.2819
Clinical Evidence of Cardioprotective Effects of SGLT2 Inhibitors
Usman, M. S., Verma, S., & Pandey, A. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_827
Type 2 Diabetes: Chronic Clinical Metabolic Effects of SGLT2 Inhibitors
Scheen, A. J. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_848 · Cited by 1
SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications
Zheng, X.-T., Xie, H.-Y., Wang, X.-H., Zhao, Y., Yang, J.-Y., Liu, Y.-X., Yuan, X.-L., Tang, H.-F., Jiang, Z., & Hu, H.-J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00604-3
“Mediation analyses from EMPA-REG OUTCOME identified increases in haematocrit and haemoglobin and reductions in uric acid as variables strongly associated with lower cardiovascular mortality during empagliflozin treatment [120].”
Kha, P. T., Nguyen, H. T. T., Garcia, M. V. F., Yoon, C., Indarua, M. A. S., Yun, H. R., Vu, T. T., Kim, H. K., & Han, J. (2026) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.1247
“…Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) demonstrated that empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, profoundly reduces major adverse cardiovascular events and hospitalizations due to heart failure in high-risk patients with T2DM [12-15].”
Elbataa, A., Mansour, A., Elazab, A., Alabed, A., Masood, R. J., Albogami, A. F., Alsalami, J. A., Hafeezallah, A. O., Alzahrani, K. M., Alotaibi, K. F., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71411
Polycythemia after SGLT2 inhibition: A post-treatment state, not a baseline subgroup
Shen, J., & Huang, F. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107247
ÜNSAL, Ö., Döngelli, H., Ünal, M. Ç., Semiz, G. G., Okumuş, A., & Demir, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15208076
“The rise in haematocrit, evident at 6 months and stable thereafter, is consistent with trial observations [21].”
Doi, Y., Arisato, T., Oka, H., Ueda, Y., Shinzawa, M., Matsumoto, A., Kitamura, H., Hamano, T., Nakazono, Y., Nishiya, Y., et al. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101590
Increased Hemoglobin With Sodium-Glucose Transporter 2 Inhibitors—A Consistent Extra Benefit?
Eckardt, K., & Koury, M. J. (2026) · JAMA · doi:10.1001/jama.2026.22329
Elazab, A., Elbataa, A., Mansour, A., Abouzid, M., Hammad, N., Hassanin, M. S., Abouzkaly, F., Alganadi, R., Ali, A. H. G., Alabed, A., et al. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70894
Inibidores do SGLT2: Gestão de Eventos Adversos na Prática Clínica
Ramalho, C., Ferreira, J. P., Junqueira, N., & Marques, P. (2026) · Acta Médica Portuguesa · doi:10.20344/amp.24617
Osmanlli, A., Conforto, R., Roy, J., Hardersen, J., & Li, Z. (2026) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2026-0216
Metadata
- Authors
- Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., Hantel, S., Bluhmki, E., & Lachin, J. M.
- Affiliations
- Yale University (US)
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Universitätsklinikum Würzburg (DE)
- Istituto di Fisiologia Clinica (IT)
- University of Freiburg (DE)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (Germany) (DE)
- George Washington University (US)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-04
- Volume
- 41
- Issue
- 2
- Pages
- 356-363
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2772204795
- Cited by
- 740
- References
- 33
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 71 · 2023: 83 · 2022: 103 · 2021: 109 · 2020: 139 · 2019: 96 · 2018: 56
- FWCI
- 62.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Eisai
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, cardiovascular mortality, mediation analysis, type 2 diabetes, EMPA-REG OUTCOME trial, hematocrit, hemoglobin, plasma volume, uric acid, fasting blood glucose, HbA1c, urine albumin-creatinine ratio, SGLT2 inhibitors
- MeSH terms
- Adult, Aged, Benzhydryl Compounds, Blood Glucose, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Dose-Response Relationship, Drug, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Placebos, Risk Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.